Core Viewpoint - Beyond Meat, Inc. is under investigation for potential violations of federal securities laws, particularly concerning the inflation of the value of certain long-lived assets [1][4]. Company Overview - Beyond Meat specializes in plant-based meat alternatives and underwent a global operations review in late 2023, during which it depreciated certain long-lived assets [3]. Stock Performance - On October 24, 2025, Beyond Meat announced an expected non-cash impairment charge for the three months ended September 27, 2025, related to its long-lived assets, which was anticipated to be material. Following this announcement, the stock price fell approximately 23%, from $2.84 per share on October 23, 2025, to $2.185 per share on October 24, 2025 [5]. - The company further delayed its earnings announcement for Q3 2025 on November 3, 2025, due to the need for additional time to complete the impairment review, leading to a significant decline in stock price on that trading day [6].

Core Points - The Avantor class action lawsuit alleges that the company and certain executives violated the Securities Exchange Act of 1934, impacting investors who purchased Avantor common stock [1][3][4] Group 1: Allegations and Financial Impact - The lawsuit claims that Avantor's competitive positioning was misrepresented, leading to substantial losses for investors due to increased competition [3] - Following the announcement of weak first quarter 2025 results, Avantor's stock price fell by over 16% after the CFO acknowledged the impact of competitive intensity [4] - In the second quarter of 2025, Avantor reported disappointing results and reduced its full-year guidance, causing a further stock price decline of more than 15% [5] - The third quarter of 2025 saw a 5% decrease in organic revenue growth, contradicting previous assurances, which led to a significant drop in stock price by over 23% [6] Group 2: Legal Process and Representation - Investors who suffered losses can seek to become lead plaintiffs in the class action lawsuit, with motions due by December 29, 2025 [2][7] - The lead plaintiff will represent the interests of all class members and can choose their legal representation [7] Group 3: Company Overview - Avantor provides mission-critical products and services across various sectors, including biopharma, healthcare, and advanced technologies [3]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit for purchasers of Fluor Corporation securities during the specified Class Period, highlighting the importance of the lead plaintiff deadline on November 14, 2025 [1]. Group 1: Class Action Details - Investors who purchased Fluor securities between February 18, 2025, and July 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [3][6]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, noting its history of successful settlements and recognition in the field [4]. - The firm has achieved significant recoveries for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Specifics - The lawsuit alleges that Fluor Corporation made false and misleading statements regarding project costs and financial guidance, which were impacted by subcontractor errors, price increases, and economic uncertainty [5]. - It is claimed that these misstatements led to a significant negative impact on Fluor's business and financial results, resulting in damages for investors when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Jasper Therapeutics - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The failure to ensure proper manufacturing processes increased the risk of confounding study results, potentially leading to disruptive cost-reduction measures and overstated business and financial prospects [5].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - James Hardie Industries plc is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the United States and Canada [4]. Allegations of Fraud - The lawsuit claims that James Hardie misled investors by stating that its North American fiber cement segment showed "inherent strength" and "underlying momentum," while in reality, sales were inflated due to inventory loading by channel partners, indicating fraudulent channel stuffing rather than genuine customer demand [5]. Stock Performance and Impact - On August 19, 2025, James Hardie disclosed a 12% decline in North American fiber cement sales, attributed to destocking efforts by customers. This revelation led to a stock price drop of $9.79 per share, or over 34%, from $28.43 to $18.64 within a day [6].

Core Insights - Stride, Inc. is under investigation for potential violations of federal securities laws, following a significant drop in stock price due to operational issues [1][4]. Company Overview - Stride, Inc. is an education technology company that offers an online platform for students across the U.S. [2]. Performance and Issues - The company previously reported "record demand" for its products and services, claiming that customer engagement was at an all-time high [2]. - However, Stride faced backlash due to unpopular platform changes that negatively impacted customer experiences, leading to a decline in student retention [3]. Stock Performance - On October 28, 2025, Stride disclosed that its growth rate did not meet expectations due to poorly executed upgrades, which resulted in a "poor customer experience" and increased withdrawal rates [4]. - The company estimated a loss of approximately 10,000-15,000 enrollments, leading to a "muted" outlook compared to previous years [4]. - Following this announcement, Stride's stock price plummeted by over 54%, dropping from $153.53 to $70.05 per share within a day [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inspire Medical Systems, Inc. common stock during the specified Class Period, indicating potential misrepresentation by the company regarding its product, Inspire V [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for investors who purchased Inspire Medical common stock between August 6, 2024, and August 4, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that Inspire Medical misrepresented the market demand for its sleep apnea device, Inspire V, and failed to disclose necessary steps for its launch, leading to investor damages when the truth was revealed [5]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by January 5, 2026, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years [4].

Core Viewpoint - Grabar Law Office is investigating claims on behalf of Inspire Medical Systems, Inc. shareholders regarding potential breaches of fiduciary duties by certain officers of the company [1] Investigation Basis - A securities fraud class action complaint alleges that Inspire Medical misled investors about the launch of its key product, the Inspire V sleep apnea device, claiming it met all necessary conditions for a successful launch, while in reality, the launch faced significant issues [3] - The complaint states that demand for Inspire V was low due to customers having excess inventory of older devices, and that the company failed to ensure proper uptake by clinicians and payors, leading to delays in adoption [3] - Following the revelation of these issues on August 4, 2025, Inspire Medical's stock price dropped by 32%, resulting in a loss of over $1.5 billion in shareholder value [3] Actions for Shareholders - Current shareholders who have held Inspire Medical shares since before August 6, 2024, can pursue corporate reforms, seek the return of funds to the company, and obtain a court-approved incentive award at no cost [2][4]

Core Viewpoint - The CarMax class action lawsuit alleges that the company and its executives misrepresented growth prospects during a specific period, leading to significant investor losses when actual performance was revealed to be declining [3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Cap v. CarMax, Inc., and it involves purchasers of CarMax securities from June 20, 2025, to September 24, 2025, with a deadline of January 2, 2026, for lead plaintiff applications [1]. - Allegations include that CarMax overstated its growth due to temporary factors related to customer behavior influenced by tariff speculation [3]. - Following the release of second-quarter fiscal year 2026 results on September 25, 2025, which showed a 5.4% decrease in retail unit sales and a 6.3% decrease in comparable store unit sales, CarMax's share price fell approximately 20% [4]. Group 2: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased CarMax securities during the class period to seek lead plaintiff status, representing the interests of the class [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 3: Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record, being ranked 1 in monetary relief for investors in securities class actions for four out of the last five years [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RCI Hospitality Holdings, Inc. during the specified class period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the securities class action is from December 15, 2021, to September 16, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the court by November 20, 2025, to represent other class members [3]. Group 2: Allegations Against RCI Hospitality - The lawsuit alleges that defendants made materially false and misleading statements, including engaging in tax fraud and bribery to cover it up [5]. - It is claimed that these actions resulted in an understatement of the legal risks facing the company, leading to misleading statements about its business and operations [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].